Evidence map›Paper›PMID 29987604›Full record

ArticleAnnals of surgical oncology2018

Long-Term Oncologic Outcomes Following Robotic Liver Resections for Primary Hepatobiliary Malignancies: A Multicenter Study.

Sidrah Khan, Rachel E Beard, Peter T Kingham, Yuman Fong, Thomas Boerner, John B Martinie, Dioneses Vrochides, Joseph F Buell, Eren Berber, Bora Kahramangil and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 5 pooled it
10.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 5 syntheses or guidelines pooled it, 93 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Robot-assisted liver resection: the real benefit so far.Langenbeck's archives of surgery · 2022
    Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 2 countries.

Sidrah KhanDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Rachel E BeardDepartment of Surgery, Rhode Island Hospital, Providence, RI, USA.
Peter T KinghamDepartment of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Yuman FongDepartment of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Thomas BoernerDepartment of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
John B MartinieDepartment of Surgery, Carolinas Medical Center, Charlotte, NC, USA.
Dioneses VrochidesDepartment of Surgery, Carolinas Medical Center, Charlotte, NC, USA.
Joseph F BuellDepartment of Surgery, Tulane University, New Orleans, LA, USA.
Eren BerberDepartment of General Surgery, Cleveland Clinic, Cleveland, OH, USA.
Bora KahramangilDepartment of General Surgery, Cleveland Clinic, Cleveland, OH, USA.
Roberto I TroisiDepartment of General, Hepatobiliary and Liver Transplantation Surgery, Ghent University Hospital Medical School, Ghent, Belgium.
Aude VanlanderDepartment of General, Hepatobiliary and Liver Transplantation Surgery, Ghent University Hospital Medical School, Ghent, Belgium.
Michele MolinariDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Allan TsungDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. tsunga@upmc.edu.
University of Pittsburgh Medical Center · USCarolinas Medical Center · USCleveland Clinic · USGhent University Hospital · BEMemorial Sloan Kettering Cancer Center · USCity Of Hope National Medical Center · USProvidence College · USTulane University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Surgery triggered immune response and liver metastasesR01CA214865 · NCI · UNIVERSITY OF VIRGINIA · PI Allan Tsung · 2018 to 2026
$3.4M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA214865
6 · The paper itself

Abstract

objectiveRobotic liver surgery (RLS) has emerged as a feasible alternative to laparoscopic or open resections with comparable perioperative outcomes. Little is known about the oncologic adequacy of RLS. The purpose of this study was to investigate the long-term oncologic outcomes for patients undergoing RLS for primary hepatobiliary malignancies.

methodsWe performed an international, multicenter, retrospective study of patients who underwent RLS for hepatocellular carcinoma (HCC), cholangiocarcinoma (CC), or gallbladder cancer (GBC) between 2006 and 2016. Age, gender, histology, resection margin status, extent of surgical resection, disease-free survival (DFS), and overall survival (OS) were retrospectively collected and analyzed.

resultsOf the 61 included patients, 34 (56%) had RLS performed for HCC, 16 (26%) for CC, and 11 (18%) for GBC. The majority of resections were nonanatomical or segmental resections (39.3%), followed by central hepatectomy (18%), left-lateral sectionectomy (14.8%), left hepatectomy (13.1%), right hepatectomy (13.1%), and right posterior segmentectomy (1.6%). R0 resection was achieved in 94% of HCC, 68% of CC, and 81.8% of GBC patients. Median hospital stay was 5 days, and conversion to open surgery was needed in seven patients (11.5%). Grade III-IV Dindo-Clavien complications occurred in seven patients with no perioperative mortality. Median follow-up was 75 months (95% confidence interval 36-113), and 5-year OS and DFS were 56 and 38%, respectively. When stratified by tumor type, 3-year OS was 90% for HCC, 65% for GBC, and 49% for CC (p = 0.01).

conclusionsRLS can be performed for primary hepatobiliary malignancies with long-term oncologic outcomes comparable to published open and laparoscopic data.

Indexed as

AdultAgedAged, 80 and overBile Duct NeoplasmsCarcinoma, HepatocellularCholangiocarcinomaFemaleFollow-Up StudiesGallbladder NeoplasmsHumansLength of StayLiver NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalPrognosis

Identifiers

PMID29987604
PMCPMC6133735
OpenAlexW2834168219

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.